P632 Etrasimod induction therapy in moderately to severely active Crohn’s disease: results from a phase 2, randomised, double-blind substudy
Geert D’Haens(Amsterdam University Medical Centers), Séverine Vermeire(KU Leuven), Marla C. Dubinsky(Icahn School of Medicine at Mount Sinai), Douglas C. Wolf(Piedmont Community College), Andrés Yarur(Cedars-Sinai Medical Center), Fabio Cataldi(Pfizer (United States)), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Silvio Danese(IRCCS Ospedale San Raffaele), J Zhang(Pfizer (United States)), Huaming Tan(Pfizer (United States)), D Dray(Pfizer (United States)), Ciro Lopez(Pfizer (United States)), Stefanie Schreiber(Otto-von-Guericke-Universität Magdeburg), Irene Modesto(Pfizer (Spain)), Michael Chiorean(Swedish Medical Center), A McDonnell(Pfizer (United Kingdom)), B E Sands(Icahn School of Medicine at Mount Sinai), Chunyan Su(Peking University), B G Feagan(Western University), G Gu
Cited by 20
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k